- Home
- OBAI vs BOLD Comparison
OBAI vs BOLD Comparison
Compare OBAI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBAI | BOLD |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 25.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | OBAI | BOLD |
|---|---|---|
| Price | $0.97 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 540.1K | 343.1K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.96 |
| 52 Week High | $19.95 | $1.78 |
Technical Indicators
Market Signals| Indicator | OBAI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 15.77 | 81.73 |
| Support Level | N/A | $1.12 |
| Resistance Level | $1.61 | N/A |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.20 | 0.05 |
| Stochastic Oscillator | 4.07 | 93.44 |
Price Performance
Historical ComparisonAbout OBAI TG-17 Inc. Common Stock
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.